StockData

Alvotech vs Repligen

ALVO and RGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and RGEN compare

Alvotech grew revenue faster over the last twelve months (19.7% versus 13.8% for Repligen).

Repligen scores higher on the StockData Score (7 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVORGEN
Size and price
Market cap–$10.4B
Share price$4.37$162.18
Change, 1 year−20.4%6.4%
Change, 5 years−55.8%−43.3%
Beta (5Y)0.371.36
Employees1,0002,000
StockData Score
Total score37 (better)
Valuation score00
Growth score23 (better)
Performance score02 (better)
Health score12 (better)
Dividend score00
Valuation
P/S–12.9×
P/B–5.0×
EV/EBITDA–98.9×
P/FCF–97.1×
FCF yield–1.0%
Fair value–$69.93
Margin of safety–−132%
Growth
Revenue growth (TTM)19.7% (better)13.8%
Revenue growth, 5Y average54.5% (better)15.0%
Net income growth (TTM)–−779%
EPS growth, 5Y average–−5.0%
Profitability
Gross margin59.8% (better)53.5%
Operating margin13.3% (better)2.3%
Net margin–−1.5%
FCF margin−19.6%13.2% (better)
Return on equity–−0.57%
Return on invested capital–0.71%
Financial health
Net debt / EBITDA10.02–
Interest coverage0.5×0.8× (better)
Current ratio1.659.88 (better)
Altman Z-score–8.41
Piotroski F-score–7
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–104%
Held by insiders67.7%0.59%
Insider net buying, 12 months–−$6.7M
Superinvestors holding–2
Short interest, % of float–11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.